Search company, investor...
Biomea Fusion company logo

Biomea Fusion

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Biomea Fusion

Biomea Fusion (NASDAQ: BMEA) is a drug development company that creates novel small molecules against genetically defined forms of cancer.

Headquarters Location

726 Main St Chamberlain Building

Redwood City, California, 94063,

United States


Missing: Biomea Fusion's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biomea Fusion's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Biomea Fusion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biomea Fusion is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Biomea Fusion Patents

Biomea Fusion has filed 1 patent.

The 3 most popular patent topics include:

  • Gene expression
  • Transcription factors
  • EC 2.1.1
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, EC 2.1.1, Gene expression, Genetics, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, EC 2.1.1, Gene expression, Genetics, Proteins



Latest Biomea Fusion News

Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022

11/11/2022 | 08:31am EST Message : *Required fields REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference. Piper Sandler 34th Annual Healthcare Conference Location: New York, NY 1x1 Meetings: Tuesday, November 29, 2022 A webcast of the fireside chat will be available on the investor page of Biomea’s website at About Biomea Fusion Biomea Fusion is a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of covalent-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases. All news about BIOMEA FUSION, INC. 08:31a

Biomea Fusion Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biomea Fusion Rank

Biomea Fusion Frequently Asked Questions (FAQ)

  • When was Biomea Fusion founded?

    Biomea Fusion was founded in 2017.

  • Where is Biomea Fusion's headquarters?

    Biomea Fusion's headquarters is located at 726 Main St, Redwood City.

  • What is Biomea Fusion's latest funding round?

    Biomea Fusion's latest funding round is IPO.

  • How much did Biomea Fusion raise?

    Biomea Fusion raised a total of $56M.

  • Who are the investors of Biomea Fusion?

    Investors of Biomea Fusion include Aisling Capital, Boxer Capital, Logos Capital, Clifton Capital, Point Sur Investors and 6 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.